Prevalence and risk factors of osteosarcopenia in elderly patients with uncontrolled type 2 diabetes.

IF 3.7 3区医学 Q2 Medicine

Endocrine Pub Date : 2024-08-19 DOI:10.1007/s12020-024-04001-0

Tingying Xiao, Shiyue Zou, Ting Luo, Jing Lai, Jixiang Ying, Min Lin

{"title":"Prevalence and risk factors of osteosarcopenia in elderly patients with uncontrolled type 2 diabetes.","authors":"Tingying Xiao, Shiyue Zou, Ting Luo, Jing Lai, Jixiang Ying, Min Lin","doi":"10.1007/s12020-024-04001-0","DOIUrl":null,"url":null,"abstract":"Purpose: To assess the prevalence of osteosarcopenia (OS) in elderly patients with type 2 diabetes mellitus (T2DM) and explore the related risk factors for developing this condition.Methods: This cross-sectional study enrolled hospitalized T2DM patients aged 60 years and older. Patients underwent assessments of total hip bone mineral density (BMD), grip strength, the Short Physical Performance Battery (SPPB), and body composition. Based on the 2019 Asian Working Group for Sarcopenia (AWGS) criteria, appendicular skeletal muscle mass (ASM), grip strength, and SPPB were measured to diagnose sarcopenia. BMD and T values of the lumbar spine and hip were measured using dual-energy X-ray absorptiometry (DXA). Osteosarcopenia was defined when both sarcopenia and osteoporosis criteria were met. Statistical analysis included binary logistic regression to identify significant risk factors.Results: A total of 254 hospitalized T2DM patients (80 males and 174 females) were included. They were divided into T2DM-OS (n = 58) and T2DM-NOS (n = 196) groups based on the presence of osteosarcopenia. The average ages were 72.724 ± 6.463 and 69.265 ± 6.035 years, respectively. The prevalence of osteosarcopenia in T2DM patients was 22.8%, with 20.7% (12 males) and 79.3% (46 females) in the T2DM-OS group. After adjusting for confounding factors, it was found that male gender (OR: 5.738, 95% CI: 1.602-20.551, P = 0.007), fasting plasma glucose (OR: 0.904, 95% CI: 0.821-0.995, P = 0.038), and ASMI (OR: 0.049, 95% CI: 0.013-0.184, P < 0.001) were major influencing factors for the development of osteosarcopenia in elderly T2DM patients.Conclusions: The prevalence of T2DM-OS is relatively high, with male gender, low fasting plasma glucose, and low ASMI identified as risk factors.","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-024-04001-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To assess the prevalence of osteosarcopenia (OS) in elderly patients with type 2 diabetes mellitus (T2DM) and explore the related risk factors for developing this condition.

Methods: This cross-sectional study enrolled hospitalized T2DM patients aged 60 years and older. Patients underwent assessments of total hip bone mineral density (BMD), grip strength, the Short Physical Performance Battery (SPPB), and body composition. Based on the 2019 Asian Working Group for Sarcopenia (AWGS) criteria, appendicular skeletal muscle mass (ASM), grip strength, and SPPB were measured to diagnose sarcopenia. BMD and T values of the lumbar spine and hip were measured using dual-energy X-ray absorptiometry (DXA). Osteosarcopenia was defined when both sarcopenia and osteoporosis criteria were met. Statistical analysis included binary logistic regression to identify significant risk factors.

Results: A total of 254 hospitalized T2DM patients (80 males and 174 females) were included. They were divided into T2DM-OS (n = 58) and T2DM-NOS (n = 196) groups based on the presence of osteosarcopenia. The average ages were 72.724 ± 6.463 and 69.265 ± 6.035 years, respectively. The prevalence of osteosarcopenia in T2DM patients was 22.8%, with 20.7% (12 males) and 79.3% (46 females) in the T2DM-OS group. After adjusting for confounding factors, it was found that male gender (OR: 5.738, 95% CI: 1.602-20.551, P = 0.007), fasting plasma glucose (OR: 0.904, 95% CI: 0.821-0.995, P = 0.038), and ASMI (OR: 0.049, 95% CI: 0.013-0.184, P < 0.001) were major influencing factors for the development of osteosarcopenia in elderly T2DM patients.

Conclusions: The prevalence of T2DM-OS is relatively high, with male gender, low fasting plasma glucose, and low ASMI identified as risk factors.

查看原文本刊更多论文

未受控制的 2 型糖尿病老年患者骨肉疏松症的患病率和风险因素。

目的：评估骨肉疏松症（OS）在老年 2 型糖尿病（T2DM）患者中的患病率，并探讨其相关风险因素：这项横断面研究招募了 60 岁及以上的住院 T2DM 患者。患者接受了全髋骨矿物质密度（BMD）、握力、短期体能测试（SPPB）和身体成分评估。根据 2019 年亚洲肌肉疏松症工作组（AWGS）的标准，测量了阑尾骨骼肌质量（ASM）、握力和 SPPB，以诊断肌肉疏松症。腰椎和髋部的 BMD 和 T 值是通过双能 X 射线吸收测定法（DXA）测量的。当同时符合 "肌肉疏松症 "和 "骨质疏松症 "的标准时，即定义为 "骨质疏松症"。统计分析包括二元逻辑回归，以确定重要的风险因素：共纳入 254 名住院 T2DM 患者（男性 80 人，女性 174 人）。根据是否存在骨质疏松症，他们被分为 T2DM-OS 组（n = 58）和 T2DM-NOS 组（n = 196）。平均年龄分别为（72.724 ± 6.463）岁和（69.265 ± 6.035）岁。T2DM患者骨肉疏松症的发病率为22.8%，其中T2DM-OS组为20.7%（12名男性）和79.3%（46名女性）。在对混杂因素进行调整后，发现男性性别（OR：5.738，95% CI：1.602-20.551，P = 0.007）、空腹血浆葡萄糖（OR：0.904，95% CI：0.821-0.995，P = 0.038）和 ASMI（OR：0.049，95% CI：0.013-0.184，P 结论：T2DM-OS 组骨质疏松症的发病率较高：T2DM-OS的发病率相对较高，其中男性、低空腹血浆葡萄糖和低ASMI被认为是风险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine 医学-内分泌学与代谢

CiteScore

6.40

自引率

5.40%

发文量

期刊介绍： Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.